Results 201 to 210 of about 3,448,762 (309)

Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial

, 2006
PINTO, STEFANIA, PROGRESS Collaborative Group   +1 more
core   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Perceived Parental Comparison, Authenticity and School Adjustment in Adolescence: A Cross-Lagged Panel Network Analysis. [PDF]

Int J Psychol
Wu W, Zhu Y, Wang Y.
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Food systems performance evaluated against targets and benchmarks reveals urgent gaps and a path to 2050. [PDF]

Nat Food
Carducci B, Schneider Lecy K, Nordhagen S, Beal T, Béné C, Gonzalez Fischer C, Herforth A, Tubiello FN, Ambikapathi R, Arunkumar K, Campeau C, Dasgupta S, DeClerck F, Del Pino Álvarez I, Guarín A, McLaren R, Vivero-Pol JL, Aburto N, Barquera S, Battersby J, Cafiero C, Conforti P, Caron P, Cattaneo A, Covic N, Elouafi I, Fabi C, Gephart JA, Fremier A, Foley P, Golden CD, Hendriks SL, Huang J, Kennedy G, Laar A, Lal R, Lidder P, Loken B, Malapit H, Marshall Q, Masuda YJ, Remans R, Resnick D, Saisana M, Sumaila UR, Torero Cullen M, Webb P, Wiebe K, Haddad L, Rosero Moncayo J, Fanzo J, Herrero M.   +51 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Longitudinal Knowledge Assessment as a driver for learning: insights from a nationwide survey of endocrinologists. [PDF]

J Endocr Soc
Gray BM, Qian J, Weng W, Chesluk BJ, Barnhart BJ, Lipner RS, McCoy RG.   +6 more
europepmc   +1 more source

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

Molecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic, Maria Concetta Vitale, Rita Siino, Emilia Di Giovanni, Carla Ferrante Bannera, Enrico Di Marco, Andrea Gottardo, Tancredi Didier Bazan Russo, Nadia Barraco, Alessandro Perez, Valerio Gristina, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia   +15 more
wiley   +1 more source

Utilization of stakeholder engagement to inform the identification of leading indicators for clinical research enrollment performance in a large integrated health care system: The VA clinical research enrollment summit. [PDF]

Contemp Clin Trials Commun
Johnson MR, Uddin AA, Wininger M, Romesser J, Velarde K, Newcomb J, Tiktin M, Dailey SA, Liu C, Huang GD.   +9 more
europepmc   +1 more source